Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures

Jacob W. Glickman; Joseph Han; Sandra Garcet; James G. Krueger; Ana B. Pavel; Emma Guttman-Yassky

doi:10.1016/j.jaip.2020.07.015

Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures

Jacob W. Glickman
, Joseph Han
, Sandra Garcet
, James G. Krueger
, Ana B. Pavel
, Emma Guttman-Yassky

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Original language	English
Pages (from-to)	3622-3625.e19
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/j.jaip.2020.07.015
State	Published - 1 Nov 2020

Access to Document

10.1016/j.jaip.2020.07.015

Cite this

@article{706e186a833640158acbc6aea784e12e,

title = "Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures",

author = "Glickman, \{Jacob W.\} and Joseph Han and Sandra Garcet and Krueger, \{James G.\} and Pavel, \{Ana B.\} and Emma Guttman-Yassky",

note = "Funding Information: Conflicts of interest: J. G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, MedImmune/AstraZeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB; and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/j.jaip.2020.07.015",

language = "English",

volume = "8",

pages = "3622--3625.e19",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "10",

}

TY - JOUR

T1 - Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures

AU - Glickman, Jacob W.

AU - Han, Joseph

AU - Garcet, Sandra

AU - Krueger, James G.

AU - Pavel, Ana B.

AU - Guttman-Yassky, Emma

N1 - Funding Information: Conflicts of interest: J. G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, MedImmune/AstraZeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB; and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/11/1

Y1 - 2020/11/1

UR - https://www.scopus.com/pages/publications/85089375421

U2 - 10.1016/j.jaip.2020.07.015

DO - 10.1016/j.jaip.2020.07.015

M3 - Article

C2 - 32702518

AN - SCOPUS:85089375421

SN - 2213-2198

VL - 8

SP - 3622-3625.e19

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 10

ER -